社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Adrian89
IP属地：未知
+关注
帖子 · 22
帖子 · 22
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Adrian89
Adrian89
·
2021-08-17
👏🏻
非常抱歉，此主贴已删除
看
1,188
回复
1
点赞
5
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-08-04
$Novavax(NVAX)$
to the moon!
看
1,023
回复
评论
点赞
3
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-07-09
$Match(MTCH)$
yay!
看
799
回复
评论
点赞
1
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-07-02
[Smile]
Look back to the first half of the year: U.S. stock indexs hit record high, these stocks are winner
(July 1) The global market officially ended in the first half of the year. On the whole, the French
Look back to the first half of the year: U.S. stock indexs hit record high, these stocks are winner
看
850
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-07-02
[Surprised]
The Stock Market Had a Great First Half. 3 Things That Could Cause it to Crash.
Stocks have soared relentlessly this year. Several factors, however, have the potential to end the p
The Stock Market Had a Great First Half. 3 Things That Could Cause it to Crash.
看
504
回复
评论
点赞
4
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-06-25
Awesome!
Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges
Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the comp
Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges
看
1,341
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-06-25
[Surprised]
Nike forecast for online sales boom, post-lockdown demand drives shares up 13%
(Reuters) -Nike Inc on Thursday forecast fiscal full-year sales ahead of Wall Street estimates, bett
Nike forecast for online sales boom, post-lockdown demand drives shares up 13%
看
612
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-06-24
[Miser]
IPO Watch: Bright Health, Monte Rosa, Confluent to Start Trading Today
Bright Health Group will start trading on the NYSE today under the ticker BHG. The company sold shar
IPO Watch: Bright Health, Monte Rosa, Confluent to Start Trading Today
看
856
回复
评论
点赞
1
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-06-24
[Smile]
Temasek-backed online pharmacy seeks funds at US$4b valuation: sources
[MAHARASHTRA] API Holdings is weighing a new funding round that could value the owner of India's lar
Temasek-backed online pharmacy seeks funds at US$4b valuation: sources
看
713
回复
评论
点赞
3
编组 21备份 2
分享
举报
Adrian89
Adrian89
·
2021-06-24
$Visa(V)$
[Miser]
看
871
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575669786186618","uuid":"3575669786186618","gmtCreate":1612576424860,"gmtModify":1615601700850,"name":"Adrian89","pinyin":"adrian89","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":17,"tweetSize":22,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":7,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.34%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":833136071,"gmtCreate":1629209536393,"gmtModify":1633686551559,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"👏🏻 ","listText":"👏🏻 ","text":"👏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/833136071","repostId":"1115558959","repostType":4,"isVote":1,"tweetType":1,"viewCount":1188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890373633,"gmtCreate":1628085221622,"gmtModify":1631885336676,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>to the moon!","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>to the moon!","text":"$Novavax(NVAX)$to the moon!","images":[{"img":"https://static.tigerbbs.com/cce04145b5b0ff63db9941caf8f1bb57","width":"1125","height":"2183"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890373633","isVote":1,"tweetType":1,"viewCount":1023,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141117570,"gmtCreate":1625841883290,"gmtModify":1631888868336,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MTCH\">$Match(MTCH)$</a>yay!","listText":"<a href=\"https://laohu8.com/S/MTCH\">$Match(MTCH)$</a>yay!","text":"$Match(MTCH)$yay!","images":[{"img":"https://static.tigerbbs.com/0aee2c6706438205a70646f687086ac4","width":"1125","height":"2183"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141117570","isVote":1,"tweetType":1,"viewCount":799,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":156771898,"gmtCreate":1625238755214,"gmtModify":1633942155935,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"[Smile] ","listText":"[Smile] ","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/156771898","repostId":"1115261715","repostType":2,"repost":{"id":"1115261715","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625125255,"share":"https://ttm.financial/m/news/1115261715?lang=&edition=full","pubTime":"2021-07-01 15:40","market":"us","language":"en","title":"Look back to the first half of the year: U.S. stock indexs hit record high, these stocks are winner","url":"https://stock-news.laohu8.com/highlight/detail?id=1115261715","media":"Tiger Newspress","summary":"(July 1) The global market officially ended in the first half of the year. On the whole, the French ","content":"<p>(July 1) The global market officially ended in the first half of the year. On the whole, the French CAC 40 index took the lead with an increase of 17.2%; the S&P 500 index and the Eurozone Stoxx 50 index increased by 14.4% Tied for second place; followed by the Mexico Composite Index and the German DAX 30 Index, with gains of 14.1% and 13.2%, respectively.</p>\n<p><img src=\"https://static.tigerbbs.com/b0699623d049666a5b8b1af052f8e0d8\" tg-width=\"670\" tg-height=\"1408\" referrerpolicy=\"no-referrer\"></p>\n<p><b>U.S. stock indexes hit record high, energy stocks are winners</b></p>\n<p>U.S. stocks in the first half of the year generally showed a trend of volatility and upward movement. The three major indexes jointly set a new record high. The S&P 500 index rose by 14.41% in the first half of the year, which has outperformed the index's average annual growth rate of 11% in the past two decades, and far outpaced the 4% increase in the first half of last year; the Nasdaq index rose by 12.54 % in the first half of the year, the Dow Jones index rose 12.73%.</p>\n<p>From the perspective of sectors and individual stocks, \"economic recovery\" and \"increasing inflation\" are the two main factors that dominated the U.S. stock market in the first half of the year. Under the influence of these two main factors, energy stocks, finance stocks and real estate stocks outperformed other sectors.</p>\n<p><img src=\"https://static.tigerbbs.com/4697acc988167e0c0adfe0713ce52b64\" tg-width=\"1924\" tg-height=\"1080\" referrerpolicy=\"no-referrer\"></p>\n<p>In the first half of this year, with the gradual promotion of the global vaccinations against the new crown, China took the lead in getting out of the shadow of the epidemic, and many European and American countries have gradually begun to loosen their blockades. With the recovery of global economy and the rebound in demand for commodities, especially the rapid rise in energy demand, Brent crude oil is the best performing asset in the first half of the year, with a yield of 44.32%.</p>\n<p>Benefiting from the explosion of demand, US energy stocks are also the top performers. Among the S&P 500 constituent stocks, five of the top ten gainers are energy stocks. Among them, Marathon Petroleum ranked first with a half-year increase of 105.55%. The other four are Diamondback Energy, Devon Energy, Occidental Petroleum and EOG Energy, with increases of 96.07%, 91.64%, 80.77% and 69.30% respectively.</p>\n<p><img src=\"https://static.tigerbbs.com/bf9454f083cdbfc0296a0d9c53d53fe6\" tg-width=\"1924\" tg-height=\"1082\" referrerpolicy=\"no-referrer\"></p>\n<p>In addition, among the constituent stocks of the Dow, energy stocks are also among the top performers. Chevron ranked fourth with an increase of 27.32%, and Caterpillar ranked eighth with an increase of 20.74%. Among the constituent stocks of the Dow, the performance of bank stocks is also remarkable.</p>\n<p>Bank stocks performed very well during the epidemic, with the help of legislators and the Federal Reserve. Three of the top five companies in the Dow's gainers are bank stocks. Among them, Goldman Sachs ranked first with increaing 44.97%; American Express ranked second with a 37.55% increase, and JPMorgan Chase ranked fifth with a 24.01% increase.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Look back to the first half of the year: U.S. stock indexs hit record high, these stocks are winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLook back to the first half of the year: U.S. stock indexs hit record high, these stocks are winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-01 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(July 1) The global market officially ended in the first half of the year. On the whole, the French CAC 40 index took the lead with an increase of 17.2%; the S&P 500 index and the Eurozone Stoxx 50 index increased by 14.4% Tied for second place; followed by the Mexico Composite Index and the German DAX 30 Index, with gains of 14.1% and 13.2%, respectively.</p>\n<p><img src=\"https://static.tigerbbs.com/b0699623d049666a5b8b1af052f8e0d8\" tg-width=\"670\" tg-height=\"1408\" referrerpolicy=\"no-referrer\"></p>\n<p><b>U.S. stock indexes hit record high, energy stocks are winners</b></p>\n<p>U.S. stocks in the first half of the year generally showed a trend of volatility and upward movement. The three major indexes jointly set a new record high. The S&P 500 index rose by 14.41% in the first half of the year, which has outperformed the index's average annual growth rate of 11% in the past two decades, and far outpaced the 4% increase in the first half of last year; the Nasdaq index rose by 12.54 % in the first half of the year, the Dow Jones index rose 12.73%.</p>\n<p>From the perspective of sectors and individual stocks, \"economic recovery\" and \"increasing inflation\" are the two main factors that dominated the U.S. stock market in the first half of the year. Under the influence of these two main factors, energy stocks, finance stocks and real estate stocks outperformed other sectors.</p>\n<p><img src=\"https://static.tigerbbs.com/4697acc988167e0c0adfe0713ce52b64\" tg-width=\"1924\" tg-height=\"1080\" referrerpolicy=\"no-referrer\"></p>\n<p>In the first half of this year, with the gradual promotion of the global vaccinations against the new crown, China took the lead in getting out of the shadow of the epidemic, and many European and American countries have gradually begun to loosen their blockades. With the recovery of global economy and the rebound in demand for commodities, especially the rapid rise in energy demand, Brent crude oil is the best performing asset in the first half of the year, with a yield of 44.32%.</p>\n<p>Benefiting from the explosion of demand, US energy stocks are also the top performers. Among the S&P 500 constituent stocks, five of the top ten gainers are energy stocks. Among them, Marathon Petroleum ranked first with a half-year increase of 105.55%. The other four are Diamondback Energy, Devon Energy, Occidental Petroleum and EOG Energy, with increases of 96.07%, 91.64%, 80.77% and 69.30% respectively.</p>\n<p><img src=\"https://static.tigerbbs.com/bf9454f083cdbfc0296a0d9c53d53fe6\" tg-width=\"1924\" tg-height=\"1082\" referrerpolicy=\"no-referrer\"></p>\n<p>In addition, among the constituent stocks of the Dow, energy stocks are also among the top performers. Chevron ranked fourth with an increase of 27.32%, and Caterpillar ranked eighth with an increase of 20.74%. Among the constituent stocks of the Dow, the performance of bank stocks is also remarkable.</p>\n<p>Bank stocks performed very well during the epidemic, with the help of legislators and the Federal Reserve. Three of the top five companies in the Dow's gainers are bank stocks. Among them, Goldman Sachs ranked first with increaing 44.97%; American Express ranked second with a 37.55% increase, and JPMorgan Chase ranked fifth with a 24.01% increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115261715","content_text":"(July 1) The global market officially ended in the first half of the year. On the whole, the French CAC 40 index took the lead with an increase of 17.2%; the S&P 500 index and the Eurozone Stoxx 50 index increased by 14.4% Tied for second place; followed by the Mexico Composite Index and the German DAX 30 Index, with gains of 14.1% and 13.2%, respectively.\n\nU.S. stock indexes hit record high, energy stocks are winners\nU.S. stocks in the first half of the year generally showed a trend of volatility and upward movement. The three major indexes jointly set a new record high. The S&P 500 index rose by 14.41% in the first half of the year, which has outperformed the index's average annual growth rate of 11% in the past two decades, and far outpaced the 4% increase in the first half of last year; the Nasdaq index rose by 12.54 % in the first half of the year, the Dow Jones index rose 12.73%.\nFrom the perspective of sectors and individual stocks, \"economic recovery\" and \"increasing inflation\" are the two main factors that dominated the U.S. stock market in the first half of the year. Under the influence of these two main factors, energy stocks, finance stocks and real estate stocks outperformed other sectors.\n\nIn the first half of this year, with the gradual promotion of the global vaccinations against the new crown, China took the lead in getting out of the shadow of the epidemic, and many European and American countries have gradually begun to loosen their blockades. With the recovery of global economy and the rebound in demand for commodities, especially the rapid rise in energy demand, Brent crude oil is the best performing asset in the first half of the year, with a yield of 44.32%.\nBenefiting from the explosion of demand, US energy stocks are also the top performers. Among the S&P 500 constituent stocks, five of the top ten gainers are energy stocks. Among them, Marathon Petroleum ranked first with a half-year increase of 105.55%. The other four are Diamondback Energy, Devon Energy, Occidental Petroleum and EOG Energy, with increases of 96.07%, 91.64%, 80.77% and 69.30% respectively.\n\nIn addition, among the constituent stocks of the Dow, energy stocks are also among the top performers. Chevron ranked fourth with an increase of 27.32%, and Caterpillar ranked eighth with an increase of 20.74%. Among the constituent stocks of the Dow, the performance of bank stocks is also remarkable.\nBank stocks performed very well during the epidemic, with the help of legislators and the Federal Reserve. Three of the top five companies in the Dow's gainers are bank stocks. Among them, Goldman Sachs ranked first with increaing 44.97%; American Express ranked second with a 37.55% increase, and JPMorgan Chase ranked fifth with a 24.01% increase.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":850,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156544825,"gmtCreate":1625232759967,"gmtModify":1633942285290,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"[Surprised] ","listText":"[Surprised] ","text":"[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/156544825","repostId":"1126312436","repostType":4,"repost":{"id":"1126312436","kind":"news","pubTimestamp":1625212145,"share":"https://ttm.financial/m/news/1126312436?lang=&edition=full","pubTime":"2021-07-02 15:49","market":"us","language":"en","title":"The Stock Market Had a Great First Half. 3 Things That Could Cause it to Crash.","url":"https://stock-news.laohu8.com/highlight/detail?id=1126312436","media":"Barrons","summary":"Stocks have soared relentlessly this year. Several factors, however, have the potential to end the p","content":"<p>Stocks have soared relentlessly this year. Several factors, however, have the potential to end the party.</p>\n<p>The S&P 500 has had its second-best first half of a year since 1998, and it hasn’t shown many signs of letting up. The index ended June up 14.4% year to date, hitting several records during the month and posting another record close on Thursday.</p>\n<p>Yet there are a couple key risks that could turn all of that around, according to Nick Colas, co-founder of DataTrek.</p>\n<p>First, there’s the possibility of an oil price shock, as the price of crude has shown little sign of cooling off. WTI crude oil is up 56% year to date and notched a new multi-year high Thursday—even amid growing expectations that OPEC will increase supply. If oil prices run hot enough, that could raise inflation to a level that—if sustained — could cause consumer demand to fall and that could surpass Federal Reserve expectations.</p>\n<p>“Suddenly higher oil prices” is atop the list of stock market concerns for Colas. “Rapidly rising oil prices will cause U.S. inflation to overshoot the Fed’s desired outcome and also stress the American consumer.”</p>\n<p>Both those things could dent the stock market, which has long benefited from the Fed’s accommodative monetary policy, especially if the Fed signals that interest-rate increases could come sooner than expected.</p>\n<p>That means the Fed will need to tread carefully when discussing rates to avoid spooking the market, Colas says.</p>\n<p>“Federal Reserve miscommunication about upcoming policy changes and/or raising interest rates too aggressively” is a second risk, Colas says. For instance, the S&P 500 dived 18% over roughly three months in late 2018 as the Fed raised rates, despite the market’s hope at that time for rates to stay put.</p>\n<p>Peaking earnings growth is the other threat to stocks, Colas says. Earnings growth for the average S&P 500 company is expected slow down to 11% in 2022 from 36% in 2021, according to FactSet, as the economy normalizes and the postpandemic recovery eases. But on average, S&P 500 stocks trade at 21.5 times expected earnings for the next 12 months, still above the index’s pre-pandemic multiple. At some point, stocks valuations will need to better reflect the expected decline in earnings growth, which would mean falling stock prices.</p>\n<p>“Valuations are high enough currently that peaking earnings could be a larger risk than before,” Colas writes.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Stock Market Had a Great First Half. 3 Things That Could Cause it to Crash.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Stock Market Had a Great First Half. 3 Things That Could Cause it to Crash.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-02 15:49 GMT+8 <a href=https://www.barrons.com/articles/stock-market-crash-risks-51625174065><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks have soared relentlessly this year. Several factors, however, have the potential to end the party.\nThe S&P 500 has had its second-best first half of a year since 1998, and it hasn’t shown many ...</p>\n\n<a href=\"https://www.barrons.com/articles/stock-market-crash-risks-51625174065\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/stock-market-crash-risks-51625174065","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126312436","content_text":"Stocks have soared relentlessly this year. Several factors, however, have the potential to end the party.\nThe S&P 500 has had its second-best first half of a year since 1998, and it hasn’t shown many signs of letting up. The index ended June up 14.4% year to date, hitting several records during the month and posting another record close on Thursday.\nYet there are a couple key risks that could turn all of that around, according to Nick Colas, co-founder of DataTrek.\nFirst, there’s the possibility of an oil price shock, as the price of crude has shown little sign of cooling off. WTI crude oil is up 56% year to date and notched a new multi-year high Thursday—even amid growing expectations that OPEC will increase supply. If oil prices run hot enough, that could raise inflation to a level that—if sustained — could cause consumer demand to fall and that could surpass Federal Reserve expectations.\n“Suddenly higher oil prices” is atop the list of stock market concerns for Colas. “Rapidly rising oil prices will cause U.S. inflation to overshoot the Fed’s desired outcome and also stress the American consumer.”\nBoth those things could dent the stock market, which has long benefited from the Fed’s accommodative monetary policy, especially if the Fed signals that interest-rate increases could come sooner than expected.\nThat means the Fed will need to tread carefully when discussing rates to avoid spooking the market, Colas says.\n“Federal Reserve miscommunication about upcoming policy changes and/or raising interest rates too aggressively” is a second risk, Colas says. For instance, the S&P 500 dived 18% over roughly three months in late 2018 as the Fed raised rates, despite the market’s hope at that time for rates to stay put.\nPeaking earnings growth is the other threat to stocks, Colas says. Earnings growth for the average S&P 500 company is expected slow down to 11% in 2022 from 36% in 2021, according to FactSet, as the economy normalizes and the postpandemic recovery eases. But on average, S&P 500 stocks trade at 21.5 times expected earnings for the next 12 months, still above the index’s pre-pandemic multiple. At some point, stocks valuations will need to better reflect the expected decline in earnings growth, which would mean falling stock prices.\n“Valuations are high enough currently that peaking earnings could be a larger risk than before,” Colas writes.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":504,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126731704,"gmtCreate":1624584113808,"gmtModify":1633950948265,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"Awesome!","listText":"Awesome!","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126731704","repostId":"2145042230","repostType":4,"repost":{"id":"2145042230","kind":"news","pubTimestamp":1624578900,"share":"https://ttm.financial/m/news/2145042230?lang=&edition=full","pubTime":"2021-06-25 07:55","market":"us","language":"en","title":"Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges","url":"https://stock-news.laohu8.com/highlight/detail?id=2145042230","media":"StreetInsider","summary":"Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the comp","content":"<p>Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for donanemab, the company’s investigational antibody therapy for Alzheimer's disease (AD).</p>\n<p>This designation is granted to companies in a bid to accelerate the development and review of therapies meant to treat serious conditions when preliminary clinical results show that the relevant drug is ahead of already available therapies that have received full FDA approval.</p>\n<p>Donanemab is an investigational antibody treatment developed by Lilly’s that targets a modified form of beta-amyloid named N3pG. In its Phase 2 trial, the company studied the efficacy and safety of the drug in patients with early Alzheimer’s disease.</p>\n<p>Stifel analyst Paul Matteis says the designation has “multiple implications for the sector.” Shares of Biogen (NASDAQ: BIIB) are down over 5% on LLY news.</p>\n<p>“LLY's plans to file donanemab this morning for accelerated approval later this year is somewhat surprising to us from a timing perspective, not because of the efficacy data (good enough relative to Adu), but because we were unsure whether the FDA would be comfortable with the size of the safety dataset. This has multiple implications for BIIB (incrementally negative) and the abeta space,” the analyst said in a note.</p>\n<p>“On the <a href=\"https://laohu8.com/S/AONE\">one</a> hand, it increases competition for BIIB: LLY's actual clinical data are less confusing, and Biogen is mired in a string of bad press regarding pricing; competition could drive down the net price. Meanwhile, it also may impact the multiple that investors put in anti-amyloid agent revenues in general. Biogen has 9 years to complete its confirmatory trial; however, LLY's second donanemab study is ongoing and may readout considerably sooner, and may set up as a relevant catalyst, positive or negative, for the plight of both drugs.”</p>\n<p>Mizuho analyst Vamil Divan raised the price target on the Buy-rated LLY to $250.00 per share from $216.00 per share as “it is difficult to argue why donanemab would NOT be approved, given the speed and depth of plaque clearance donanemab demonstrated in TRAILBLAZER-ALZ and prior studies.”</p>\n<p>“We increase our probability of donanemab's regulatory approval to 90% (from 60%), assuming an accelerated approval will be based on amyloid plaque clearance, something donanemab has already consistently demonstrated. We also move up our donanemab launch to the start of 2023 (from 2024), but acknowledge this could even prove to still be a little conservative. However, we note that BIIB has guided to only “modest” revenues this year after its June 7 approval, so would assume fairly limited donanemab sales in 2022 even if Lilly gets an approval in the middle of the year. On the other hand, Lilly may be able to leverage some of what BIIB is doing now to secure coverage and access for anti-amyloid therapies, allowing for potentially more rapid market uptake. Lilly would also have the potential advantage of having confirmatory clinical data much sooner than BIIB, given their TRAILBLAZER-ALZ 2 trial is ongoing, with recruitment expected to be completed by year-end and full data expected by mid-2023,” Divan writes in a report on LLY.</p>\n<p>“We now estimate donanemab probability-adjusted sales of ~$11Bn in 2030, with room for further upside given the size of the Alzheimer's market. Our donanemab estimate changes drive our Lilly price target to $250 (from $217), with room for upside on a faster approval, a higher price (we currently assume $30K net per patient per year in the US and $15K in the EU and Japan), more rapid market uptake and/or higher peak sales. Our price target based on a 75%/25% blend of discounted cash flow (DCF) valuation at $259 and relative valuation at $222. Our DCF is based on cash flows forecasted through 2030, along with a 6.5% discount rate and a 0.5% rate of terminal growth. Our relative valuation is based on a 30.0x multiple of 2021 P/E using our estimate of Lilly’s 2021 EPS.”</p>\n<p>Lilly plans to apply for the biologics license (BLA) for donanemab under the expedited approval pathway later in 2021 based on data from Phase 2. The safety and efficacy of the drug are also being assessed in the ongoing Phase 3 study.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Surges After Getting Breakthrough Therapy Designation From FDA, Analyst Raises PT and Sees Approval Chance at 90%, Biogen Plunges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 07:55 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=18600310><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18600310\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","BIIB":"渤健公司"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18600310","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145042230","content_text":"Shares of Eli Lilly and Company (NYSE: LLY) are up over 9% in today’s trading session after the company obtained the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for donanemab, the company’s investigational antibody therapy for Alzheimer's disease (AD).\nThis designation is granted to companies in a bid to accelerate the development and review of therapies meant to treat serious conditions when preliminary clinical results show that the relevant drug is ahead of already available therapies that have received full FDA approval.\nDonanemab is an investigational antibody treatment developed by Lilly’s that targets a modified form of beta-amyloid named N3pG. In its Phase 2 trial, the company studied the efficacy and safety of the drug in patients with early Alzheimer’s disease.\nStifel analyst Paul Matteis says the designation has “multiple implications for the sector.” Shares of Biogen (NASDAQ: BIIB) are down over 5% on LLY news.\n“LLY's plans to file donanemab this morning for accelerated approval later this year is somewhat surprising to us from a timing perspective, not because of the efficacy data (good enough relative to Adu), but because we were unsure whether the FDA would be comfortable with the size of the safety dataset. This has multiple implications for BIIB (incrementally negative) and the abeta space,” the analyst said in a note.\n“On the one hand, it increases competition for BIIB: LLY's actual clinical data are less confusing, and Biogen is mired in a string of bad press regarding pricing; competition could drive down the net price. Meanwhile, it also may impact the multiple that investors put in anti-amyloid agent revenues in general. Biogen has 9 years to complete its confirmatory trial; however, LLY's second donanemab study is ongoing and may readout considerably sooner, and may set up as a relevant catalyst, positive or negative, for the plight of both drugs.”\nMizuho analyst Vamil Divan raised the price target on the Buy-rated LLY to $250.00 per share from $216.00 per share as “it is difficult to argue why donanemab would NOT be approved, given the speed and depth of plaque clearance donanemab demonstrated in TRAILBLAZER-ALZ and prior studies.”\n“We increase our probability of donanemab's regulatory approval to 90% (from 60%), assuming an accelerated approval will be based on amyloid plaque clearance, something donanemab has already consistently demonstrated. We also move up our donanemab launch to the start of 2023 (from 2024), but acknowledge this could even prove to still be a little conservative. However, we note that BIIB has guided to only “modest” revenues this year after its June 7 approval, so would assume fairly limited donanemab sales in 2022 even if Lilly gets an approval in the middle of the year. On the other hand, Lilly may be able to leverage some of what BIIB is doing now to secure coverage and access for anti-amyloid therapies, allowing for potentially more rapid market uptake. Lilly would also have the potential advantage of having confirmatory clinical data much sooner than BIIB, given their TRAILBLAZER-ALZ 2 trial is ongoing, with recruitment expected to be completed by year-end and full data expected by mid-2023,” Divan writes in a report on LLY.\n“We now estimate donanemab probability-adjusted sales of ~$11Bn in 2030, with room for further upside given the size of the Alzheimer's market. Our donanemab estimate changes drive our Lilly price target to $250 (from $217), with room for upside on a faster approval, a higher price (we currently assume $30K net per patient per year in the US and $15K in the EU and Japan), more rapid market uptake and/or higher peak sales. Our price target based on a 75%/25% blend of discounted cash flow (DCF) valuation at $259 and relative valuation at $222. Our DCF is based on cash flows forecasted through 2030, along with a 6.5% discount rate and a 0.5% rate of terminal growth. Our relative valuation is based on a 30.0x multiple of 2021 P/E using our estimate of Lilly’s 2021 EPS.”\nLilly plans to apply for the biologics license (BLA) for donanemab under the expedited approval pathway later in 2021 based on data from Phase 2. The safety and efficacy of the drug are also being assessed in the ongoing Phase 3 study.","news_type":1,"symbols_score_info":{"BIIB":0.9,"LLY":0.9}},"isVote":1,"tweetType":1,"viewCount":1341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126491661,"gmtCreate":1624580840353,"gmtModify":1633951047864,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"[Surprised] ","listText":"[Surprised] ","text":"[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126491661","repostId":"1151333793","repostType":4,"repost":{"id":"1151333793","kind":"news","pubTimestamp":1624578319,"share":"https://ttm.financial/m/news/1151333793?lang=&edition=full","pubTime":"2021-06-25 07:45","market":"us","language":"en","title":"Nike forecast for online sales boom, post-lockdown demand drives shares up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151333793","media":"Reuters","summary":"(Reuters) -Nike Inc on Thursday forecast fiscal full-year sales ahead of Wall Street estimates, bett","content":"<p>(Reuters) -Nike Inc on Thursday forecast fiscal full-year sales ahead of Wall Street estimates, betting on its online business, higher demand as lockdowns ease, and its tried-and-tested strategy of limiting stock for popular products.</p>\n<p>The sneaker maker’s shares rose nearly 13% after the bell as the company also posted better-than-expected quarterly earnings and revenue.</p>\n<p>After staying at home for more than a year and limiting themselves to leisure-wear and comfortable pajamas, consumers are back to buying sneakers for running and hiking as they return to their routines, thanks to rapid vaccinations.</p>\n<p>There were definite reasons for optimism and confidence, like the return to sport, Chief Financial Officer Matthew Friend said on an earnings call, adding that Nike has already begun to see an acceleration in its sport performance business.</p>\n<p>Beaverton, Oregon-based Nike said fiscal 2022 revenue is estimated to grow by low double-digits and surpass $50 billion. Analysts had expected revenue of $48.46 billion for fiscal 2022, according to Refinitiv.</p>\n<p>First-half growth is expected to be slightly higher than second half growth, Friend said.</p>\n<p>In Nike’s biggest market, North America, fourth-quarter revenue more than doubled to $5.38 billion and beat the average analysts’ estimate of $4.31 billion.</p>\n<p>Total gross margin rose 8.5 percentage points to 45.8% versus last year, boosted in part by the company’s direct to consumer business and fewer charges related to factory cancellations. Analysts expected gross margin of 43.96%, according to Refinitiv.</p>\n<p>Net income came in at $1.51 billion, or 93 cents per share, for the quarter ended May 31, compared with a loss of $790 million, or 51 cents per share, a year earlier.</p>\n<p>Total revenue nearly doubled to $12.34 billion from a year ago, when the pandemic was at its peak. Analysts were expecting revenue of $11.01 billion and earnings of 51 cents per share, according to IBES data from Refinitiv.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike forecast for online sales boom, post-lockdown demand drives shares up 13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike forecast for online sales boom, post-lockdown demand drives shares up 13%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 07:45 GMT+8 <a href=https://www.reuters.com/article/nike-results/update-3-nike-forecast-for-online-sales-boom-post-lockdown-demand-drives-shares-up-13-idUSL3N2O63ZI><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Nike Inc on Thursday forecast fiscal full-year sales ahead of Wall Street estimates, betting on its online business, higher demand as lockdowns ease, and its tried-and-tested strategy of ...</p>\n\n<a href=\"https://www.reuters.com/article/nike-results/update-3-nike-forecast-for-online-sales-boom-post-lockdown-demand-drives-shares-up-13-idUSL3N2O63ZI\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NKE":"耐克"},"source_url":"https://www.reuters.com/article/nike-results/update-3-nike-forecast-for-online-sales-boom-post-lockdown-demand-drives-shares-up-13-idUSL3N2O63ZI","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151333793","content_text":"(Reuters) -Nike Inc on Thursday forecast fiscal full-year sales ahead of Wall Street estimates, betting on its online business, higher demand as lockdowns ease, and its tried-and-tested strategy of limiting stock for popular products.\nThe sneaker maker’s shares rose nearly 13% after the bell as the company also posted better-than-expected quarterly earnings and revenue.\nAfter staying at home for more than a year and limiting themselves to leisure-wear and comfortable pajamas, consumers are back to buying sneakers for running and hiking as they return to their routines, thanks to rapid vaccinations.\nThere were definite reasons for optimism and confidence, like the return to sport, Chief Financial Officer Matthew Friend said on an earnings call, adding that Nike has already begun to see an acceleration in its sport performance business.\nBeaverton, Oregon-based Nike said fiscal 2022 revenue is estimated to grow by low double-digits and surpass $50 billion. Analysts had expected revenue of $48.46 billion for fiscal 2022, according to Refinitiv.\nFirst-half growth is expected to be slightly higher than second half growth, Friend said.\nIn Nike’s biggest market, North America, fourth-quarter revenue more than doubled to $5.38 billion and beat the average analysts’ estimate of $4.31 billion.\nTotal gross margin rose 8.5 percentage points to 45.8% versus last year, boosted in part by the company’s direct to consumer business and fewer charges related to factory cancellations. Analysts expected gross margin of 43.96%, according to Refinitiv.\nNet income came in at $1.51 billion, or 93 cents per share, for the quarter ended May 31, compared with a loss of $790 million, or 51 cents per share, a year earlier.\nTotal revenue nearly doubled to $12.34 billion from a year ago, when the pandemic was at its peak. Analysts were expecting revenue of $11.01 billion and earnings of 51 cents per share, according to IBES data from Refinitiv.","news_type":1,"symbols_score_info":{"NKE":0.9}},"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126920343,"gmtCreate":1624542568182,"gmtModify":1634004649706,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"[Miser] ","listText":"[Miser] ","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126920343","repostId":"1186095717","repostType":4,"repost":{"id":"1186095717","kind":"news","pubTimestamp":1624538824,"share":"https://ttm.financial/m/news/1186095717?lang=&edition=full","pubTime":"2021-06-24 20:47","market":"us","language":"en","title":"IPO Watch: Bright Health, Monte Rosa, Confluent to Start Trading Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1186095717","media":"The Wall Street Journal","summary":"Bright Health Group will start trading on the NYSE today under the ticker BHG. The company sold shar","content":"<p>Bright Health Group will start trading on the NYSE today under the ticker BHG. The company sold shares in its initial public offering at $18 apiece.</p>\n<p>Monte Rosa Therapeutics Inc. will join the Nasdaq Global Select Market as GLUE after selling shares at $19 each.</p>\n<p>Confluent Inc. will make its debut as CFLT. The company's shares were sold in the IPO for $36 each.</p>\n<p>Miromatrix Medical will make its debut on the Nasdaq as MIRO after selling shares at $9 each.</p>\n<p>Grove Inc. will trade as GRVI after selling its stock in the IPO at $5 apiece.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Watch: Bright Health, Monte Rosa, Confluent to Start Trading Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Watch: Bright Health, Monte Rosa, Confluent to Start Trading Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 20:47 GMT+8 <a href=https://www.wsj.com/livecoverage/stock-market-news-live-updates-062421/card/ktmYlQj6UfmkqxIEmORt><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bright Health Group will start trading on the NYSE today under the ticker BHG. The company sold shares in its initial public offering at $18 apiece.\nMonte Rosa Therapeutics Inc. will join the Nasdaq ...</p>\n\n<a href=\"https://www.wsj.com/livecoverage/stock-market-news-live-updates-062421/card/ktmYlQj6UfmkqxIEmORt\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CFLT":"Confluent, Inc.","GLUE":"Monte Rosa Therapeutics"},"source_url":"https://www.wsj.com/livecoverage/stock-market-news-live-updates-062421/card/ktmYlQj6UfmkqxIEmORt","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186095717","content_text":"Bright Health Group will start trading on the NYSE today under the ticker BHG. The company sold shares in its initial public offering at $18 apiece.\nMonte Rosa Therapeutics Inc. will join the Nasdaq Global Select Market as GLUE after selling shares at $19 each.\nConfluent Inc. will make its debut as CFLT. The company's shares were sold in the IPO for $36 each.\nMiromatrix Medical will make its debut on the Nasdaq as MIRO after selling shares at $9 each.\nGrove Inc. will trade as GRVI after selling its stock in the IPO at $5 apiece.","news_type":1,"symbols_score_info":{"BHG":0.9,"CFLT":0.9,"GLUE":0.9,"GRVI":0.9,"MIRO":0.9}},"isVote":1,"tweetType":1,"viewCount":856,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128591727,"gmtCreate":1624522398269,"gmtModify":1634004911284,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"[Smile] ","listText":"[Smile] ","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128591727","repostId":"1114144195","repostType":4,"repost":{"id":"1114144195","kind":"news","pubTimestamp":1624522045,"share":"https://ttm.financial/m/news/1114144195?lang=&edition=full","pubTime":"2021-06-24 16:07","market":"us","language":"en","title":"Temasek-backed online pharmacy seeks funds at US$4b valuation: sources","url":"https://stock-news.laohu8.com/highlight/detail?id=1114144195","media":"Bloomberg","summary":"[MAHARASHTRA] API Holdings is weighing a new funding round that could value the owner of India's lar","content":"<p>[MAHARASHTRA] API Holdings is weighing a new funding round that could value the owner of India's largest online pharmacy chain at about US$4 billion, according to people familiar with the matter.</p>\n<p>The company is considering raising about US$300 million and its existing investors including TPG Capital and Temasek Holdings could participate, said the people, who asked not to be identified as the discussions are private.</p>\n<p>API, which owns India's first e-pharmacy unicorn PharmEasy, intends to use the proceeds for potential acquisitions particularly in the diagnostic area, one of the people said.</p>\n<p>A new round would mark the second fundraising by API Holdings within a few months after securing about US$350 million in April. The firm last raised funds from a clutch of investors including Prosus Ventures, TPG and Temasek, according to a press release at that time.</p>\n<p>PharmEasy has so far delivered more than 15 million orders from medicine to diagnostic kits to healthcare products, serving over five million families, according to its website.</p>\n<p>Deliberations are ongoing and details of the fundraising could still change, the people said. Siddharth Shah, API's co-founder and chief executive officer, didn't respond to messages for comment, while representatives for Temasek and TPG declined to comment.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Temasek-backed online pharmacy seeks funds at US$4b valuation: sources</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTemasek-backed online pharmacy seeks funds at US$4b valuation: sources\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 16:07 GMT+8 <a href=https://www.businesstimes.com.sg/garage/temasek-backed-online-pharmacy-seeks-funds-at-us4b-valuation-sources><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>[MAHARASHTRA] API Holdings is weighing a new funding round that could value the owner of India's largest online pharmacy chain at about US$4 billion, according to people familiar with the matter.\nThe ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/garage/temasek-backed-online-pharmacy-seeks-funds-at-us4b-valuation-sources\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.businesstimes.com.sg/garage/temasek-backed-online-pharmacy-seeks-funds-at-us4b-valuation-sources","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114144195","content_text":"[MAHARASHTRA] API Holdings is weighing a new funding round that could value the owner of India's largest online pharmacy chain at about US$4 billion, according to people familiar with the matter.\nThe company is considering raising about US$300 million and its existing investors including TPG Capital and Temasek Holdings could participate, said the people, who asked not to be identified as the discussions are private.\nAPI, which owns India's first e-pharmacy unicorn PharmEasy, intends to use the proceeds for potential acquisitions particularly in the diagnostic area, one of the people said.\nA new round would mark the second fundraising by API Holdings within a few months after securing about US$350 million in April. The firm last raised funds from a clutch of investors including Prosus Ventures, TPG and Temasek, according to a press release at that time.\nPharmEasy has so far delivered more than 15 million orders from medicine to diagnostic kits to healthcare products, serving over five million families, according to its website.\nDeliberations are ongoing and details of the fundraising could still change, the people said. Siddharth Shah, API's co-founder and chief executive officer, didn't respond to messages for comment, while representatives for Temasek and TPG declined to comment.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":713,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128593921,"gmtCreate":1624522332963,"gmtModify":1631886289750,"author":{"id":"3575669786186618","authorId":"3575669786186618","name":"Adrian89","avatar":"https://static.tigerbbs.com/36b4b75806fbfc44154d0cc81727c284","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575669786186618","authorIdStr":"3575669786186618"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/V\">$Visa(V)$</a>[Miser] ","listText":"<a href=\"https://laohu8.com/S/V\">$Visa(V)$</a>[Miser] ","text":"$Visa(V)$[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128593921","isVote":1,"tweetType":1,"viewCount":871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}